# OnCo record paper-schmitz-genetics-pathogenesis-dlbcl-nejm-2018 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-schmitz-genetics-pathogenesis-dlbcl-nejm-2018/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-schmitz-genetics-pathogenesis-dlbcl-nejm-2018" ;
  schema:name "Genetics and pathogenesis of diffuse large B-cell lymphoma"@en ;
  schema:alternateName "Schmitz 2018"@en, "MCD, BN2, N1 and EZB subtypes"@en, "National Cancer Institute genetic subtypes"@en ;
  schema:description "Sequencing 574 lymphomas found four genetic patterns that recur, two of which depend on a signalling route that an existing tablet can block."@en ;
  schema:url <https://onco.cc/key-papers/paper-schmitz-genetics-pathogenesis-dlbcl-nejm-2018/> ;
  schema:dateModified "2026-10-01"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa1801445>, <https://pubmed.ncbi.nlm.nih.gov/29641966/>, <https://europepmc.org/article/MED/29641966> ;
  onco:tag "lymphoma-evidence" ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa1801445> ;
  schema:datePublished "2018"^^xsd:gYear ;
  schema:author "Schmitz R, Wright GW, Huang DW, et al." ;
  onco:related <https://onco.cc/key-papers/paper-chapuy-molecular-subtypes-dlbcl-nat-med-2018/>, <https://onco.cc/key-papers/paper-wright-lymphgen-genetic-subtypes-dlbcl-cancer-cell-2020/>, <https://onco.cc/key-papers/paper-phoenix-ibrutinib-r-chop-non-gcb-dlbcl-jco-2019/>, <https://onco.cc/roadmaps/lymphoma-roadmap/> ;
  onco:cancers <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/diagnostics/>, <https://onco.cc/fronts/targeted-therapy/>, <https://onco.cc/fronts/drug-discovery/> ;
  onco:technologies <https://onco.cc/technologies/wes-wgs/>, <https://onco.cc/terms/ngs/> ;
  onco:targets <https://onco.cc/targets/myd88/>, <https://onco.cc/targets/cd79b/>, <https://onco.cc/targets/bcl6/>, <https://onco.cc/targets/notch1/>, <https://onco.cc/targets/notch2/>, <https://onco.cc/targets/ezh2/>, <https://onco.cc/targets/bcl2/>, <https://onco.cc/targets/btk/> ;
  onco:institutions <https://onco.cc/institutions/nci/> ;
  onco:pathways <https://onco.cc/pathways/bcr-signalling/> ;
  onco:terms <https://onco.cc/terms/cell-of-origin/> ;
  onco:trials <https://onco.cc/trials/phoenix/>, <https://onco.cc/trials/arched/> ;
  onco:people <https://onco.cc/people/louis-staudt/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-tumor-heterogeneity/>, <https://onco.cc/bottlenecks/b-biomarker-validation/>, <https://onco.cc/bottlenecks/b-trial-design/> ;
  onco:journals <https://onco.cc/journals/nejm/> .